Nectar Lifesciences Limited (NECLIFE.BO)
INR 23.21
(4.03%)
INR 23.21
(4.03%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 49.95 Million INR | 120.66% |
| 2022 | -241.83 Million INR | -196.55% |
| 2021 | 250.47 Million INR | 134.19% |
| 2020 | -732.64 Million INR | -330.47% |
| 2019 | 317.89 Million INR | -33.22% |
| 2018 | 476 Million INR | -8.94% |
| 2017 | 522.72 Million INR | -5.54% |
| 2016 | 553.38 Million INR | 2.02% |
| 2015 | 542.4 Million INR | -18.15% |
| 2014 | 662.64 Million INR | 6.73% |
| 2013 | 620.86 Million INR | -27.59% |
| 2012 | 857.42 Million INR | 17.11% |
| 2011 | 732.16 Million INR | -29.74% |
| 2010 | 1.04 Billion INR | 12.91% |
| 2009 | 922.88 Million INR | 74.21% |
| 2008 | 529.74 Million INR | -29.12% |
| 2007 | 747.39 Million INR | 59.94% |
| 2006 | 467.28 Million INR | 23.01% |
| 2005 | 379.88 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 29.69 Million INR | 401.2% |
| 2023 Q2 | 10.15 Million INR | -44.23% |
| 2023 FY | 49.95 Million INR | 120.66% |
| 2023 Q1 | 18.2 Million INR | -49.95% |
| 2023 Q4 | 5.92 Million INR | -62.19% |
| 2023 Q3 | 15.66 Million INR | 54.33% |
| 2022 Q4 | 36.37 Million INR | 139.16% |
| 2022 FY | -241.83 Million INR | -196.55% |
| 2022 Q1 | 38.99 Million INR | -66.56% |
| 2022 Q2 | -224.71 Million INR | -676.29% |
| 2022 Q3 | -92.87 Million INR | 58.67% |
| 2021 Q4 | 116.6 Million INR | 19.82% |
| 2021 FY | 250.47 Million INR | 134.19% |
| 2021 Q3 | 97.31 Million INR | 422.83% |
| 2021 Q2 | 18.61 Million INR | 3.75% |
| 2021 Q1 | 17.94 Million INR | 104.38% |
| 2020 Q4 | -409.74 Million INR | -407.67% |
| 2020 Q1 | -169.03 Million INR | -327.83% |
| 2020 Q3 | -80.71 Million INR | -10.35% |
| 2020 Q2 | -73.14 Million INR | 56.73% |
| 2020 FY | -732.64 Million INR | -330.47% |
| 2019 Q1 | 137.01 Million INR | -21.73% |
| 2019 Q3 | 82.17 Million INR | 235.35% |
| 2019 FY | 317.89 Million INR | -33.22% |
| 2019 Q4 | 74.19 Million INR | -9.71% |
| 2019 Q2 | 24.5 Million INR | -82.12% |
| 2018 Q3 | 109.06 Million INR | 84.71% |
| 2018 Q1 | 132.83 Million INR | 0.0% |
| 2018 Q4 | 175.06 Million INR | 60.52% |
| 2018 FY | 476 Million INR | -8.94% |
| 2018 Q2 | 59.04 Million INR | -55.55% |
| 2017 FY | 522.72 Million INR | -5.54% |
| 2016 FY | 553.38 Million INR | 2.02% |
| 2015 Q3 | - INR | 0.0% |
| 2015 FY | 542.4 Million INR | -18.15% |
| 2014 FY | 662.64 Million INR | 6.73% |
| 2014 Q3 | - INR | 0.0% |
| 2013 FY | 620.86 Million INR | -27.59% |
| 2012 FY | 857.42 Million INR | 17.11% |
| 2011 FY | 732.16 Million INR | -29.74% |
| 2010 FY | 1.04 Billion INR | 12.91% |
| 2009 FY | 922.88 Million INR | 74.21% |
| 2008 FY | 529.74 Million INR | -29.12% |
| 2007 FY | 747.39 Million INR | 59.94% |
| 2006 FY | 467.28 Million INR | 23.01% |
| 2005 FY | 379.88 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 99.189% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 99.843% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 98.939% |
| Granules India Limited | 4.05 Billion INR | 98.768% |
| Indoco Remedies Limited | 984.6 Million INR | 94.927% |
| Achyut Healthcare Limited | 5.73 Million INR | -771.424% |
| Ajanta Pharma Limited | 8.16 Billion INR | 99.388% |
| Alkem Laboratories Limited | 17.95 Billion INR | 99.722% |
| Alpa Laboratories Limited | 167.76 Million INR | 70.226% |
| Brooks Laboratories Limited | -195.91 Million INR | 125.495% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 96.907% |
| Bajaj HealthCare Limited | -837.93 Million INR | 105.961% |
| Bliss GVS Pharma Limited | 754.54 Million INR | 93.38% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 99.91% |
| Eris Lifesciences Limited | 3.91 Billion INR | 98.726% |
| FDC Limited | 3.05 Billion INR | 98.363% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 100.333% |
| Gufic Biosciences Limited | 861.35 Million INR | 94.201% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 98.813% |
| Ipca Laboratories Limited | 5.47 Billion INR | 99.087% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | 77.763% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 125.319% |
| Lasa Supergenerics Limited | -217.3 Million INR | 122.986% |
| Laurus Labs Limited | 1.6 Billion INR | 96.889% |
| Lupin Limited | 19.14 Billion INR | 99.739% |
| Mankind Pharma Limited | 19.12 Billion INR | 99.739% |
| Medicamen Biotech Limited | 109.31 Million INR | 54.304% |
| Medico Remedies Limited | 82.9 Million INR | 39.753% |
| Megasoft Limited | -127.46 Million INR | 139.187% |
| NATCO Pharma Limited | 13.88 Billion INR | 99.64% |
| Piramal Pharma Limited | 178.2 Million INR | 71.97% |
| RPG Life Sciences Limited | 876.6 Million INR | 94.302% |
| Sigachi Industries Limited | 571.8 Million INR | 91.264% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 99.948% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 98.337% |
| Syncom Formulations (India) Limited | 253.14 Million INR | 80.268% |
| Unichem Laboratories Limited | -704.74 Million INR | 107.088% |
| Wanbury Limited | 559.56 Million INR | 91.073% |
| Windlas Biotech Limited | 581.87 Million INR | 91.416% |
| ZIM Laboratories Limited | 172.46 Million INR | 71.037% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 99.871% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 101.29% |
| Divi's Laboratories Limited | 16 Billion INR | 99.688% |
| Hester Biosciences Limited | 188.89 Million INR | 73.556% |
| Procter & Gamble Health Limited | 2 Billion INR | 97.515% |
| Amrutanjan Health Care Limited | 449.72 Million INR | 88.893% |
| Bal Pharma Limited | 73.92 Million INR | 32.429% |
| Strides Pharma Science Limited | -706.14 Million INR | 107.074% |
| Venus Remedies Limited | 284.9 Million INR | 82.468% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 97.697% |
| Shilpa Medicare Limited | 318.74 Million INR | 84.329% |
| Aarti Drugs Limited | 1.71 Billion INR | 97.086% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 96.284% |
| Suven Life Sciences Limited | -1.05 Billion INR | 104.754% |
| Ind-Swift Limited | 142.31 Million INR | 64.901% |
| Valiant Laboratories Limited | 3.19 Million INR | -1462.891% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 99.096% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 100.88% |
| Themis Medicare Limited | 435.23 Million INR | 88.524% |
| Hikal Limited | 696.02 Million INR | 92.823% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 99.698% |
| Sequent Scientific Limited | -358.69 Million INR | 113.926% |
| Novartis India Limited | 851.9 Million INR | 94.137% |
| Wockhardt Limited | -4.63 Billion INR | 101.079% |
| Jubilant Pharmova Limited | 771 Million INR | 93.521% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -604.315% |
| Neuland Laboratories Limited | 3 Billion INR | 98.335% |
| Morepen Laboratories Limited | 961.59 Million INR | 94.806% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | 65.791% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 155.061% |